| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President, CMO | CMO, Hematology
2 companies
Jane Huang is President, CMO at PRLD, with reported holdings spanning 2 companies. Jane Huang's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $329K at current prices.
Our model assigns Jane Huang a strong insider score of 81/100, based on 18 past trades. Over a 12-month horizon, all 18 of those trades were profitable, with an average 12-month return of +49.9%.
Jane Huang's largest disclosed position is in PRLD as President, CMO, worth about $329K. The PRLD filings lean toward selling, a net 13,280 shares.
Jane Huang has 72 Form 4 filings on record from June 2017 to June 2026, across 3 companies: Director at Protara Therapeutics (TARA), 2021–2026; President, CMO at Prelude Therapeutics (PRLD), 2022–2025; CMO, Hematology at BeOne Medicines (ONC), 2017–2021.
The 290 reported transactions were 200 open-market sales, 52 option exercises, 17 option or other derivative awards and 12 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 48 sales worth about $39.8M.
The largest open-market sale was 21,000 shares of ONC at an average $332.42 on July 15, 2021, about $7.0M. Twelve months later ONC was down 47%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 6, 2023 | PRLD Prelude Therapeutics Inc | President, CMO | Sale+OE | 13,280 | $6.12 | $81,273.60 | -35.4% | -24.5% | -23.7% | |
| Dec 14, 2021 | ONC Beone Medicines Ltd. | CMO, Hematology | Sale+OE | 1,500 | $278.14 | $417,211.00 | - | -47.3% | -24.9% | |
| Dec 1, 2021 | ONC Beone Medicines Ltd. | CMO, Hematology | Sell | 1,049 | $359.86 | $377,492.69 | -100% | -38.6% | -44.7% | |
| Nov 17, 2021 | ONC Beone Medicines Ltd. | CMO, Hematology | Sale+OE | 1,500 | $381.34 | $572,003.39 | - | -42.2% | -47.2% | |
| Oct 19, 2021 | ONC Beone Medicines Ltd. | CMO, Hematology | Sale+OE | 1,500 | $372.78 | $559,163.00 | - | -36.3% | -58.8% | |
| Sep 20, 2021 | ONC Beone Medicines Ltd. | CMO, Hematology | Sale+OE | 6,000 | $397.96 | $2,387,773.97 | - | -31.3% | -61.4% | |
| Sep 13, 2021 | ONC Beone Medicines Ltd. | CMO, Hematology | Sell | 12,901 | $358.14 | $4,620,389.59 | -100% | -22.3% | -55.3% | |
| Sep 2, 2021 | ONC Beone Medicines Ltd. | CMO, Hematology | Sell | 1,087 | $318.88 | $346,620.90 | -100% | +5.7% | -49.9% | |
| Jul 15, 2021 | ONC Beone Medicines Ltd. | CMO, Hematology | Sale+OE | 12,921 | $332.26 | $4,293,088.61 | - | +7.4% | -46.6% | |
| Jun 29, 2021 | ONC Beone Medicines Ltd. | CMO, Hematology | Sale+OE | 1,925 | $354.97 | $683,323.00 | - | +5.6% | -54.6% |